Etoposide as a Key Therapeutic Agent in Lung Cancer: Mechanisms, Efficacy, and Emerging Strategies
- 문서 유형
- 연구출판물 · 리뷰논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES26(2) · 2025
- 피인용
- Web of Science 35Scopus 37
- FWCI (Scopus)
- 2.84
- JCR IF
- JCR 2024 4.9
- ISSN
- 1661-6596
저자
- 장정윤제1저자Pusan Natl Univ, Coll Pharm, Res Inst Drug Dev, Dept Pharm, Busan 46241, South Korea
- Kim, DonghwanKorea Food Res Inst, Funct Food Mat Res Grp, Wanju Gun 55365, Jeollabuk Do, South Korea
- 임은옥교신저자Pusan Natl Univ, Coll Pharm, Res Inst Drug Dev, Dept Pharm, Busan 46241, South Korea
- 김남득교신저자Pusan Natl Univ, Coll Pharm, Res Inst Drug Dev, Dept Pharm, Busan 46241, South Korea
초록
Topoisomerase II inhibitors, particularly etoposide, have long been integral to the treatment of lung cancer, especially small cell lung cancer. This review comprehensively examines the mechanisms of action of etoposide, its clinical efficacy, and its role in current lung cancer treatment regimens. Etoposide exerts its anticancer effects by inducing DNA strand breaks through the inhibition of topoisomerase II, leading to cancer cell apoptosis. Despite their widespread use, challenges such as drug resistance, toxicity, and limited efficacy in non-small cell lung cancer have spurred ongoing research on combination therapies and novel drug formulations. Emerging therapeutic strategies include the integration of etoposide with immunotherapy, targeted therapies, and novel drug delivery systems aimed at enhancing the therapeutic window and overcoming drug resistance. This article aims to inform the development of more effective treatment strategies by providing a critical overview of the clinical applications of etoposide and exploring future directions for lung cancer therapy.
키워드
anticanceretoposidelung cancertopoisomerase II inhibitorsPHASE-III TRIAL1ST-LINE TREATMENTTHORACIC RADIOTHERAPYCHEMOTHERAPYCARBOPLATINCISPLATINCISPLATIN/ETOPOSIDERESISTANCEINHIBITORSREGIMEN
식별자
- Scopus EID
- 2-s2.0-85216035022
- WoS UID
- 001404306700001



로그인
연구물 목록으로